Bevacizumab, from a clinical practice standpoint, slightly increases the efficacy of chemotherapy in HER-2 negative advanced breast cancer, although a close follow-up monitoring for adverse events must be adopted. This evidence concerns the gene ERBB2 and breast cancer.